Plasmatic Markers in Hemorrhagic Stroke
Author Information
Author(s): Marginean IC, Stanca DM, Vacaras V, Soritau O, Margiean M, Muresanu DF
Primary Institution: Department of Neurology, University of Medicine and Pharmacy, Cluj–Napoca
Hypothesis
Can biological markers be used to differentiate between ischemic and hemorrhagic stroke?
Conclusion
Biological markers like GFAP, S100B, and Apo C–III may help in diagnosing and managing acute stroke patients.
Supporting Evidence
- GFAP was detectable in 81% of ICH patients but only in 5% of IS patients.
- The mean GFAP serum concentration was significantly higher in patients with ICH.
- S100B levels increase in plasma after brain damage due to ischemic stroke.
- High blood S100B concentrations are associated with infarct size and outcome.
- APO C–III is overexpressed in acute ischemic stroke patients compared to acute intracerebral hemorrhage patients.
Takeaway
Doctors are looking for simple blood tests to tell if someone has had a stroke and what kind it is, which can help them treat the patient better.
Methodology
The study reviewed various biological markers and their potential use in diagnosing stroke types.
Limitations
Disability does not always correlate with the amount of brain tissue lost, and the blood-brain barrier may delay the release of proteins into the bloodstream.
Participant Demographics
93 patients with ischemic stroke and 42 patients with intracerebral hemorrhage.
Want to read the original?
Access the complete publication on the publisher's website